Navigation Links
Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer

Scientists to Present Data on Innovative Oncology Compounds at the American Association for Cancer Research Annual Meeting

ABBOTT PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- For decades, scientists have looked for new therapies that target cancer. Researchers now know that cancer cells have several unique characteristics -- they require new blood vessels to deliver oxygen and nutrients (angiogenesis), they grow uncontrollably (proliferation), they travel throughout the body (metastasis), and they escape programmed cell death, a natural process by which the body rids itself of damaged or unwanted cells (apoptosis). Robust preclinical data shows that several compounds in Abbott's oncology pipeline interfere with these vital processes. Data on two of these compounds will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18 in Los Angeles.

During the meeting, scientists from independent academic institutions and Abbott will present data on Abbott's Bcl-2 family protein inhibitor (ABT-263). This compound, currently in early clinical development, corrects defects in cancer cells that allow them to escape programmed cell death. They will also present data on an investigational PARP inhibitor (ABT-888) that enhances the effectiveness of common cancer therapies that damage DNA in cancer cells.

    Presentation highlights include:


    ABT-263

    --  "ABT-263:  An orally bioavailable Bcl-2 family protein inhibitor"

        [Oral presentation, Sunday, April 15, 1 p.m., Hall A]

    --  "Pediatric preclinical testing program (PPTP) evaluation of the Bcl-2

         inhibitor ABT-263"

        [Oral presentation, Tuesday, April 17, 3:55 p.m., Room 404 A-B]


    ABT-888

    --  "The poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888 potentiates

         the antitumor activity of temozolomide in the B16F10 syngeneic

         melanoma model: Correlation with pharmacokinetic levels and a

  
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. NIEHS Researchers Identify Enzyme Critical in DNA Replication
11. Stanford Researchers Find Brain Pathway of Depression in Rats
Post Your Comments:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Soligenix, Inc. (Soligenix or the Company) (OTC ... biopharmaceutical company, announced today promising preliminary results from ... or BDP) in a canine gastrointestinal acute radiation ... with SGX202 demonstrated statistically significant (p=0.04) improvement in ...
... BOTHELL, Wash., Jan. 18, 2011 BioLife Solutions, ... announced today that it has significantly increased its ... regenerative medicine industry.  The worldwide regenerative medicine market ... hospitals, which are developing cell and tissue-based products ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 2BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 3BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 4BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 5
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Reporter , TUESDAY, Feb. 22 (HealthDay News) -- Nitroglycerin ... counter bone loss, a new study suggests. As ... is increasing. Nitroglycerin appears to increase bone density ... over newer and more costly drugs, the researchers noted. ...
... new type of nanoparticle that could safely and effectively deliver ... The new particles, described in the Feb. 20 issue of ... can carry synthetic versions of proteins normally produced by viruses. ... to that produced by live virus vaccines but should ...
... (Feb. 22, 2011) Three American College of Radiology ... the ACR Board of Chancellors will outline strategies for ... minimize medical radiation exposure at a Feb. 24, 25 ... "NIH Summit to Focus on Management of Radiation Dose ...
... NY) In an advance that could improve battlefield ... of Medicine of Yeshiva University have used tiny ... loss. Nanoparticles containing nitric oxide (NO) were infused into ... circulation and protect vital organs. The research was reported ...
... TUESDAY, Feb. 22 (HealthDay News) -- The increasingly commonplace ... labor for convenience rather than for medical necessity entails ... suggests. The new report, which highlights the negative ... first-time mothers, indicates that going that route increases the ...
... respond differently to their crying babies than do non-depressed ... at the University of Oregon, is much more muted ... An infant crying is normal, but how mothers respond ... professor of psychology. For years, Ablow has studied the ...
Cached Medicine News:Health News:Nitroglycerin Ointment Might Strengthen Bones 2Health News:Nitroglycerin Ointment Might Strengthen Bones 3Health News:MIT engineers design new nanoparticle that could lead to vaccines for HIV, malaria, other diseases 2Health News:MIT engineers design new nanoparticle that could lead to vaccines for HIV, malaria, other diseases 3Health News:ACR commission and committee chairs and former board chair to present at NIH Radiation Dose Summit 2Health News:Nanoparticles increase survival after blood loss 2Health News:Induced Labor Linked to Raised Risks for First-Time Moms 2Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3
... The programmer for the ITREL 3 ... programmer and the Model 7457 MemoryMod ... indicated for the treatment of chronic nausea ... drug therapies are not providing adequate relief ...
... Rapid diagnosis of influenza A ... important due to the availability ... diagnosis of influenza using Clearview ... can lead to reduced hospital ...
... ability of the visual system to ... are,some pathological conditions that reduce contrast ... test will help in the identification ... and reduced visual acuity often occur ...
...
Medicine Products: